Navigation Links
Vermillion Files Plan of Reorganization
Date:11/24/2009

rmillion can be found on the Web at www.vermillion.com.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) --- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

OVA1(TM) Test is a trademark of Vermillion Inc.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize ovarian cancer or OVA1 diagnostics products in 2009 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and c
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
2. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
3. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
6. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
7. Vermillion Receives Award From the Society of Gynecologic Oncologists
8. Sinovac Files Shelf Registration Statement
9. deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
10. Derma Sciences Files S-1 Registration Statement
11. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... July 10, 2014 CBPartners, a global ... has launched a new website. The redesigned site ... increased access to the firm’s thought pieces, blog posts, ... ideal platform to showcase our insights, capabilities, and to ... CBPartners’ Chief Executive Officer, Cyrus Chowdhury. “An enhanced ...
(Date:7/10/2014)... July 10, 2014 Best ... believes that having family close by during a ... in whether or not the process is successful, ... its website at http://www.bestdrugrehabilitation.com/success-stories/ . , The ... video testimonials from several Best Drug Rehabilitation graduates ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
(Date:7/10/2014)... A new study from Colorado School of Public Health ... remains a major problem in the Navajo Nation and ... Native Americans is abysmal with more than three times ... Terrence Batliner, DDS, MBA, associate director of the Center ... Public Health. "The number one problem is access to ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Study finds widespread oral health problems among Navajo 2
... at the Financial Communications Forum, New York, ... named John,Hancock Retirement Plan Service,s "EZ Route" post-enrollment ... Award for Customer Advocacy in,Financial Services. Sponsored by ... at the Financial Communications Forum in New York, ...
... Framework includes sample RFI language, advantages of ... concept, WASHINGTON, April 16 The ... representing the country,s,national business leaders, policymakers and ... for health care purchasers to buy,health care ...
... Mike Roban has been named Vice,President of Sales of ... worldwide emergency assistance and insurance company.,A respected veteran with ... travel assistance services, Roban will add further depth and ... to joining MEDEX Global Group, Roban was the senior ...
... urged all 27 EU countries to continue to seek ... that osteoporosis places on health systems throughout Europe, as ... status of osteoporosis management across member states. , The ... to prepare the report, Osteoporosis in the European Union ...
... by researchers at the Mayo Clinic site in Florida ... largely caused by inherited genetic mutations that pass through ... of years. These genetic influences, which can be small ... that the neurodegenerative disease mostly occurs in a random ...
... ImQuest Life Sciences today,presented important new results ... development candidate, IQP-0410, and lead topical microbicide,development ... Ph.D. (Executive Vice President and Chief Scientific ... Microbicide Research & Development),were invited to speak ...
Cached Medicine News:Health News:John Hancock's 'EZ Route' Post-Enrollment Education Program Wins 2008 Insight Award for Customer Advocacy in Financial Services 2Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 2Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 3Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 4Health News:MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 2Health News:IOF calls for concerted support for second EU osteoporosis audit 2Health News:Different mutations in single gene suggest Parkinson's is primarily an inherited genetic disorder 2Health News:Different mutations in single gene suggest Parkinson's is primarily an inherited genetic disorder 3Health News:Different mutations in single gene suggest Parkinson's is primarily an inherited genetic disorder 4Health News:Different mutations in single gene suggest Parkinson's is primarily an inherited genetic disorder 5Health News:ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528 2
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed to ... Farnsworth D15 test is used to separate ... The L'Anthony Desaturated test is much more ... deficiency from Normal. Both of these ...
... as easy as 1-2-3: just three simple steps ... with rapid information before they leave your office. ... the appropriate therapy; no more follow-up appointments or ... A Test is a rapid immunochromatographic assay for ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: